WASHINGTON (dpa-AFX) - Myriad Genetics, Inc. (MYGN) reported net income for the third quarter of $21.5 million or $0.29 per share, compared to $36.8 million or $0.48 per share for the year-ago quarter.
Excluding items, adjusted net income for the third quarter was $29.3 million or $0.40 per share, compared to $46.2 million or $0.60 per share in the prior year quarter.
Total revenue for the third quarter fell 1.6% to $180.0 million from $182.9 million a year ago.
Analysts polled by Thomson Reuters expected the company to earn $0.39 per share on revenue of $183.34 million for the third quarter. Analysts' estimates typically exclude special items.
Looking forward to the fourth quarter, the company forecasts revenues of $187 million to $189 million, earnings of of $0.28 to $0.30 per share and adjusted earnings of $0.40 to $0.42 per share. Analysts currently expect the company to earn $0.49 per share on revenue of $197.97 million for the fourth quarter.
For the fiscal year 2015, the company now forecasts revenues of $720 million to $722 million and adjusted earnings of $1.44 to $1.46 per share. Previously, the company forecast revenues of $730 million to $740 million and adjusted earnings of $1.50 to $1.55 per share.
Analysts currently expect the company to earn $1.52 per share on revenue of $734.19 million for the fiscal year 2015.
Copyright RTT News/dpa-AFX
Kostenloser Wertpapierhandel auf Smartbroker.de